United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trump administration officials on Monday deny a New York Times report that says they passed when Pfizer offered in late summer to sell the U.S. government additional doses. They also play down news that Moderna and Pfizer won't take part in Trump's vaccine summit.

Capitol Report: White House denies report saying it passed when Pfizer offered additional vaccine doses

Moderna

The two companies will be conspicuous by their absence at an event some administration sources are viewing as a publicity stunt for President Donald Trump.

Pfizer And Moderna Steer Clear Of White House Vaccine Summit

The move would be a pivotal moment in the pandemic as public health officials say the U.S. is likely to face its worst health crisis in history this winter.

FDA could authorize Pfizer's Covid vaccine this week as U.S. deaths surge

Johnson & Johnson

Pfizer or JNJ for vaccine run? While Pfizer's stock and Johnson & Johnson's stock look hot with vaccines, data suggests Merck stock is better than both!

Buy Pfizer Stock Or JNJ For Vaccine Run?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. Data from 30 patients with relapsed or refractory multiple myeloma showed manageable safety across all subcutaneous dose levels with no dose-limiting toxicities observed, and 83% of patients achieved a clinical response at the highest dose level. T

Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma

Sangamo Therapeutics

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th - 8th. The oral pres

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy

AstraZeneca

AstraZeneca Plc's  (NASDAQ: AZN) partner, the Serum Institute of India, applied for emergency use authorization of the former's COVID-19 vaccine candidate on Sunday, as per the Press Trust Of India. What Happened: The SII is conducting the phase-3 clinical trial of the Oxford-AstraZeneca vaccine — dubbed Covishield — in India, which is co-sponsored by the Indian Council of Medical Research, as per PTI.

AstraZeneca Follows Pfizer In Seeking India Emergency Use Approval For COVID-19 Vaccine

The stock price of Pfizer Inc. (NYSE:PFE) increased 6.3% this past week as it went from $37.95 per share on November 30 morning to a closing price of $40.34 on Friday, December 4. These are some of the reasons why it happened.

PFE Stock Price Increased 6.3% This Past Week: Why It Happened

Pfizer Inc. (NYSE: PFE) is seeking emergency approval for its COVID-19 vaccine in India, according to media sources in the country. What Happened: The vaccine developed together with BioNTech SE - ADR (NASDAQ: BNTX) was approved in the U.K. last week.

Pfizer Applies For Emergency Approval For COVID-19 Vaccine In India: Media Reports

AbbVie

Bristol-Myers

The Oracle of Omaha knows a good bargain when he sees one.

3 Value Stocks Warren Buffett Owns That You Should Consider Buying Too

Pfizer's vaccine for COVID looks promising and should boost revenues substantially. The company is trading at an inexpensive valuation and offers an above-average dividend yield.

Pfizer: Coronavirus Vaccine Playing Out, Still Inexpensive And Offering A High Yield

BioNTech SE

Bahrain joins U.K. in authorizing emergency use of Pfizer–BioNTech vaccine

Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) is first among coronavirus vaccine developers to secure authorization for emergency use of candidate BNT162b2, with the first approval granted by U.K. regulators. Scale-Down Previously Disclosed: An analyst at BofA Securities shrugged off a Thursday report in The Wall Street Journal that hinted at manufacturing constraints, resulting in a modest pullback in Pfizer shares.

Pfizer's Scaled-Down COVID-19 Vaccine Manufacturing Plan Is Old News: BofA

Pfizer's Covid-19 vaccine has been approved for emergency use in the United Kingdom, with initial shots likely to be given as soon as next week. The U.K is the first western country to ratify the shot and the country is expected to be allotted between four million to five million doses of the.

What The Approval Of The Covid Vaccine In The U.K Means For Pfizer Stock

Vaxart

Vaccine makers of all sizes and development stages face crucial news this month.

3 Top Coronavirus Stocks to Watch in December

3 COVID Vaccine Stocks to Invest in for the Long Run

Supply chain problems reportedly caused Pfizer to cut projections for its COVID-19 vaccine rollout.  Sources close to the Pfizer vaccine development told The Wall Street Journal delays scaling up raw materials, coupled with an "unprecedented" effort to deliver millions of vaccines within a year, led the company to miss target shipments.

Supply chain delays marred Pfizer's initial vaccine rollout plans, but the company says it will still deliver on the supply it promised the US

The company puts the blame on difficulties with raw materials, among other challenges.

Pfizer to Ship Half as Many Coronavirus Vaccine Doses as Originally Planned in Initial Phase

Pfizer stock tumbled Thursday after the company reportedly slashed its expectations for coronavirus vaccine deliveries in 2020 due to supply-chain issues. The post Pfizer Stock Trips As Supply-Chain Issues Hamper Covid Vaccine Delivery appeared first on Investor's Business Daily.

Pfizer Stock Trips As Supply-Chain Issues Hamper Covid Vaccine Delivery

The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards.

Pfizer shares fall on report company cut its Covid vaccine rollout target

Pfizer (NYSE: PFE) shares fell after reports emerged the company expects to ship half of the COVID-19 vaccines it originally planned for this year due to supply-chain issues, according to The Wall Street Journal. What To Know: In November, Pfizer and BioNTech's (NASDAQ: BNTX) vaccine candidate showed a 95% efficacy rate.

Supply Chain Issues Cause Pfizer To Cut Initial COVID-19 Vaccine Shipments In Half

"The U.K. has decided to do it a little bit differently, they've gone over it very quickly," Fauci told Sky News.

Dr. Fauci says UK's Pfizer Covid vaccine review 'much less deep' than U.S.

At the 2020 Forbes Healthcare Summit, Albert Bourla is already looking beyond his company's vaccine success and into a post-pandemic world.

Pfizer CEO Is ‘Confident' In Covid-19 Vaccine Rollout And Looking Beyond The Pandemic

Pfizer had been submitting data on its vaccine on a "rolling basis" to the U.K., meaning regulators there were able to review the data in real-time.

Why Pfizer's Covid vaccine has been authorized in the U.K. but not the U.S. yet

With FDA meetings near, Moderna and Pfizer enter a new phase of the vaccine race.

News for Pfizer Stock (PFE)